Dupilumab in chronic spontaneous urticaria

Chronic spontaneous urticaria is a chronic inflammatory disease that can persist despite antihistamine or anti-IgE (omalizumab) treatments. In two randomized, placebo-controlled, double-blind Phase 3 clinical trials, researchers here compared dupilumab to placebo in patients with symptomatic chronic spontaneous urticaria on antihistamines. One trial involved omalizumab-naïve patients, while the other involved omalizumab intolerant or poor responders. The safety profile was consistent with the known adverse effects of dupilumab. The effects of dupilumab were weak in patients intolerant or poor responders to omalizumab. On the other hand, the effect was interesting in omalizumab-naive patients.